Skip to Content

Case Overview

Status:Status:Investigating
Company Name:Company Name:NeuroPace, Inc.
Ticker:Ticker:NPCE
Related Attorneys:Lead Attorneys:Thomas W. Elrod
Related Practices:Related Practices:Securities
On November 13, 2026, NeuroPace released its third quarter 2026 financial results, announcing third quarter revenue of $23.1 million, a 1.1% decline year-over-year, and cutting its full year 2026 revenue guidance to $91 million to $92 million, down from $99.5 million to $101.5 million. NeuroPace CEO Joel Becker stated, “Our third quarter results fell short of our expectations,” attributing those results to “local operational issues” (such as staffing, physician availability, and diagnostic procedure capacity) at “several of our largest accounts,” as well as sales force disruption and the continued impact of the Company’s exit from the stereoelectroencephalography (“SEEG”) distribution business. Just three months earlier, on August 11, 2026, NeuroPace increased its full-year 2026 revenue guidance to $99.5 million to $101.5 million, up from $99 million to $101 million. In August, CFO Patrick Williams stated, “The increase in total revenue guidance reflects improved visibility into service revenue, which we now expect to be approximately $1 million for the full year, up from previous guidance of $500,000… We expect our third quarter RNS revenue growth to be similar to our first half RNS growth rate of approximately 20% year-over-year.” On the November news, the price of NeuroPace shares declined by $4.46 per share, or approximately 37.1%, from $12.02 per share on November 12, 2026 to close at $$7.56 on November 13, 2026.

Contact Us About This Case

You may share a link to this page on any of the sites listed below or send link via email: